Activation of pulmonary neutral endopeptidase in experimental congestive heart failure

D. M. Heublein, A. Luchner, Daniel Dean Borgeson, J. A. Grantham, S. M. Sandberg, John C Jr. Burnett

Research output: Contribution to journalArticle

Abstract

Neutral Endopeptidase 24.11 (NEP) is a zinc metalloprotease which degrades the Natriuretic Peptides, ANP, BNP, and CNP and may limit their biological actions which include natriuresis, renin inhibition, vasodilitation and anti-mitogenesis. While inhibition of NEP has been proposed as a novel pharmacological approach in the treatment of hypertension and congestive heart failure (CHF), little information exists regarding the presence and activity of NEP in normal and diseased tissue. The objective of the current study is to quantify NEP activity in the left ventricle (LV) and lung under normal conditions and in experimental CHF utilizing a canine model of rapid ventricular pacing, and to visualize NEP activity by immunohistochemistry. NEP activity (pmol/min/mg protein) was measured utilizing a combined enzymatic-fluorometric assay. CHF (n=5) was characterized by LV dysfunction (EF 21±2%) LV dilatation (LVEDd 48±1 mm), increased LV mass-index (4.5±0.1 gr.kg.) and decreased mean arterial pressure (85±3 mmHg.). In control tissue (n=4), NEP activity was present in LV (16±10 pmol/min/mg protein) and lung (31±8 pmol/min/mg protein, p=n.s.). While NEP activity in LV tissue demonstrated a tendency to decrease during CHF (4.3±0.5 pmol/min/mg protein, p=n.s.), pulmonary NEP activity increased (65±11, p=0.05 vs control). Immunohistochemistry revealed that staining in CHF is localized to ventricular myocytes and pulmonary endothelial and epithelial cells. These studies support the concent of a differential regulation of NEP activity in cardiopulmonary tissue during CHF.

Original languageEnglish (US)
JournalFASEB Journal
Volume11
Issue number3
StatePublished - 1997

Fingerprint

Neprilysin
heart failure
proteinases
Heart Failure
Chemical activation
lungs
Lung
Heart Ventricles
Tissue
immunohistochemistry
Proteins
proteins
Immunohistochemistry
natriuretic peptides
renin
Natriuretic Peptides
Natriuresis
Endothelial cells
Enzyme Assays
Metalloproteases

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Activation of pulmonary neutral endopeptidase in experimental congestive heart failure. / Heublein, D. M.; Luchner, A.; Borgeson, Daniel Dean; Grantham, J. A.; Sandberg, S. M.; Burnett, John C Jr.

In: FASEB Journal, Vol. 11, No. 3, 1997.

Research output: Contribution to journalArticle

Heublein, D. M. ; Luchner, A. ; Borgeson, Daniel Dean ; Grantham, J. A. ; Sandberg, S. M. ; Burnett, John C Jr. / Activation of pulmonary neutral endopeptidase in experimental congestive heart failure. In: FASEB Journal. 1997 ; Vol. 11, No. 3.
@article{fadc61e21aab4e4b9a01691f1905a2bb,
title = "Activation of pulmonary neutral endopeptidase in experimental congestive heart failure",
abstract = "Neutral Endopeptidase 24.11 (NEP) is a zinc metalloprotease which degrades the Natriuretic Peptides, ANP, BNP, and CNP and may limit their biological actions which include natriuresis, renin inhibition, vasodilitation and anti-mitogenesis. While inhibition of NEP has been proposed as a novel pharmacological approach in the treatment of hypertension and congestive heart failure (CHF), little information exists regarding the presence and activity of NEP in normal and diseased tissue. The objective of the current study is to quantify NEP activity in the left ventricle (LV) and lung under normal conditions and in experimental CHF utilizing a canine model of rapid ventricular pacing, and to visualize NEP activity by immunohistochemistry. NEP activity (pmol/min/mg protein) was measured utilizing a combined enzymatic-fluorometric assay. CHF (n=5) was characterized by LV dysfunction (EF 21±2{\%}) LV dilatation (LVEDd 48±1 mm), increased LV mass-index (4.5±0.1 gr.kg.) and decreased mean arterial pressure (85±3 mmHg.). In control tissue (n=4), NEP activity was present in LV (16±10 pmol/min/mg protein) and lung (31±8 pmol/min/mg protein, p=n.s.). While NEP activity in LV tissue demonstrated a tendency to decrease during CHF (4.3±0.5 pmol/min/mg protein, p=n.s.), pulmonary NEP activity increased (65±11, p=0.05 vs control). Immunohistochemistry revealed that staining in CHF is localized to ventricular myocytes and pulmonary endothelial and epithelial cells. These studies support the concent of a differential regulation of NEP activity in cardiopulmonary tissue during CHF.",
author = "Heublein, {D. M.} and A. Luchner and Borgeson, {Daniel Dean} and Grantham, {J. A.} and Sandberg, {S. M.} and Burnett, {John C Jr.}",
year = "1997",
language = "English (US)",
volume = "11",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "3",

}

TY - JOUR

T1 - Activation of pulmonary neutral endopeptidase in experimental congestive heart failure

AU - Heublein, D. M.

AU - Luchner, A.

AU - Borgeson, Daniel Dean

AU - Grantham, J. A.

AU - Sandberg, S. M.

AU - Burnett, John C Jr.

PY - 1997

Y1 - 1997

N2 - Neutral Endopeptidase 24.11 (NEP) is a zinc metalloprotease which degrades the Natriuretic Peptides, ANP, BNP, and CNP and may limit their biological actions which include natriuresis, renin inhibition, vasodilitation and anti-mitogenesis. While inhibition of NEP has been proposed as a novel pharmacological approach in the treatment of hypertension and congestive heart failure (CHF), little information exists regarding the presence and activity of NEP in normal and diseased tissue. The objective of the current study is to quantify NEP activity in the left ventricle (LV) and lung under normal conditions and in experimental CHF utilizing a canine model of rapid ventricular pacing, and to visualize NEP activity by immunohistochemistry. NEP activity (pmol/min/mg protein) was measured utilizing a combined enzymatic-fluorometric assay. CHF (n=5) was characterized by LV dysfunction (EF 21±2%) LV dilatation (LVEDd 48±1 mm), increased LV mass-index (4.5±0.1 gr.kg.) and decreased mean arterial pressure (85±3 mmHg.). In control tissue (n=4), NEP activity was present in LV (16±10 pmol/min/mg protein) and lung (31±8 pmol/min/mg protein, p=n.s.). While NEP activity in LV tissue demonstrated a tendency to decrease during CHF (4.3±0.5 pmol/min/mg protein, p=n.s.), pulmonary NEP activity increased (65±11, p=0.05 vs control). Immunohistochemistry revealed that staining in CHF is localized to ventricular myocytes and pulmonary endothelial and epithelial cells. These studies support the concent of a differential regulation of NEP activity in cardiopulmonary tissue during CHF.

AB - Neutral Endopeptidase 24.11 (NEP) is a zinc metalloprotease which degrades the Natriuretic Peptides, ANP, BNP, and CNP and may limit their biological actions which include natriuresis, renin inhibition, vasodilitation and anti-mitogenesis. While inhibition of NEP has been proposed as a novel pharmacological approach in the treatment of hypertension and congestive heart failure (CHF), little information exists regarding the presence and activity of NEP in normal and diseased tissue. The objective of the current study is to quantify NEP activity in the left ventricle (LV) and lung under normal conditions and in experimental CHF utilizing a canine model of rapid ventricular pacing, and to visualize NEP activity by immunohistochemistry. NEP activity (pmol/min/mg protein) was measured utilizing a combined enzymatic-fluorometric assay. CHF (n=5) was characterized by LV dysfunction (EF 21±2%) LV dilatation (LVEDd 48±1 mm), increased LV mass-index (4.5±0.1 gr.kg.) and decreased mean arterial pressure (85±3 mmHg.). In control tissue (n=4), NEP activity was present in LV (16±10 pmol/min/mg protein) and lung (31±8 pmol/min/mg protein, p=n.s.). While NEP activity in LV tissue demonstrated a tendency to decrease during CHF (4.3±0.5 pmol/min/mg protein, p=n.s.), pulmonary NEP activity increased (65±11, p=0.05 vs control). Immunohistochemistry revealed that staining in CHF is localized to ventricular myocytes and pulmonary endothelial and epithelial cells. These studies support the concent of a differential regulation of NEP activity in cardiopulmonary tissue during CHF.

UR - http://www.scopus.com/inward/record.url?scp=33750231291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750231291&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33750231291

VL - 11

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 3

ER -